Article
Exploring CAR T-Cell Therapy During the COVID-19 Pandemic: What's on the Horizon for CAR T-Cell Therapies
Author(s):
This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor T cells. Join us Tuesday, June 2, 2020 at 8 PM EST.
Date/Time: Tuesday, June 2, 2020 at 8 PM EST
This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor (CAR) T cells. We will feature a panel of leading experts to discuss important topics and considerations surrounding CAR T-cell therapies and the patient populations impacted during this time.
Course Topics:
- Highlights from ASCO CAR T-cell abstracts and presentations
- Updates on CAR T-cell clinical trials
- New and novel CAR T-cell therapies
Associate Professor Section Chief, Indolent Lymphoma Section Chief, New Drug Development Department Lymphoma/Myeloma UT MD Anderson Cancer Center
Matthew Lunning, DO, Associate Professor, Internal Medicine Medical Director, Lymphoma Research Division of Oncology & Hematology University of Nebraska Medical Center
Ahmed Galal, MD, FRACP, MSc,Professor of Medicine Division of Hematologic Malignancies and Cellular Therapy Duke University School of Medicine
Sponsored By:
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
